Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

KaloBios Announces New Transparency Measures for Drug Prices

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

Although it has no drugs on the market, KaloBios Pharmaceuticals has announced that it will limit price increases to the rate of inflation or Consumer Price Index, and will do…

Continue ReadingKaloBios Announces New Transparency Measures for Drug Prices

AbbVie, Genentech Scoop Up FDA Approval for Leukemia Drug Venclexta

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

The FDA has given the green light to the chronic lymphocytic leukemia treatment Venclexta, which will be marketed by AbbVie and Roche’s Genentech unit. Source: Drug Industry Daily

Continue ReadingAbbVie, Genentech Scoop Up FDA Approval for Leukemia Drug Venclexta

Senate Committee Eyes Contempt Proceedings Against Valeant’s Pearson

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

Two lawmakers are mulling contempt proceedings against outgoing Valeant CEO J. Michael Pearson after he failed to provide a deposition on Friday as part of an investigation into drug pricing.…

Continue ReadingSenate Committee Eyes Contempt Proceedings Against Valeant’s Pearson

FDA: Consider Real-World Usage Early On To Avoid Medication Errors

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

The FDA is pressing drugmakers to build risk assessments into their drug designs early on to cut down on medication errors. Source: Drug Industry Daily

Continue ReadingFDA: Consider Real-World Usage Early On To Avoid Medication Errors

WHO Letter Blasts Cadila on Data Integrity Concerns and GMP Issues

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

Shortly after receiving an FDA warning letter for alleged major quality deficiencies, an Indian vaccine maker was slammed for data integrity issues and GMP violations by the World Health Organization.…

Continue ReadingWHO Letter Blasts Cadila on Data Integrity Concerns and GMP Issues

FDA Bashes Two Indian Drugmakers for Allegedly Flouting Procedures

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

The FDA has slammed two Indian drugmakers — Emcure Pharmaceuticals and Lupin —for purported GMP violations. Source: Drug GMP Report

Continue ReadingFDA Bashes Two Indian Drugmakers for Allegedly Flouting Procedures

Quality Control Fears Prompt Letters to Four Dietary Supplement Makers

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

Four supplement makers were hit with FDA warning letters March 22 over alleged quality control violations and related issues. Source: Drug GMP Report

Continue ReadingQuality Control Fears Prompt Letters to Four Dietary Supplement Makers

FDA Hits Compounders With Letters Over Sterility Issues, Misbranding

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

Two compounding operations are facing FDA allegations of producing adulterated drugs and doing so without prescriptions following agency inspections. Source: Drug GMP Report

Continue ReadingFDA Hits Compounders With Letters Over Sterility Issues, Misbranding

Expert: Focus on Data Consistency to Streamline Quality, Compliance

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

The fragmented nature of the modern manufacturing sector necessitates focusing less on technology and more on integration, according to an industry expert. Source: Drug GMP Report

Continue ReadingExpert: Focus on Data Consistency to Streamline Quality, Compliance

Contract Manufacturer Gets Letter Over GMP Concerns, Labeling Issues

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

A contract manufacturer is being hit with a warning letter over a slew of GMP and labeling violations. Source: Drug GMP Report

Continue ReadingContract Manufacturer Gets Letter Over GMP Concerns, Labeling Issues
  • Go to the previous page
  • 1
  • …
  • 592
  • 593
  • 594
  • 595
  • 596
  • 597
  • 598
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.